semaglutide and kidney problems in patients with overweight or obesity chronic disease without diabetes: a randomized double-blind placebo-controlled clinical trial can semaglutide cause kidney problems

human evidence for the blend is absent and individual results vary

Key findings from OASIS 4 Double-blind, placebo-controlled, 64-week, phase 3 trial (N=307) Mean weight loss: 13.6% (semaglutide) vs 2.2% (placebo) 5% weight loss in 79.2% (semaglutide) vs 31.1% (placebo) Improvements in physical functioning and cardiometabolic markers Serious adverse events were lower in the semaglutide group (3.9% vs 8.8%) This could be a key player particularly among patients who are needle-averse, travel often, or seek simpler dosing options

There is also a risk of regaining lost weight

A typical tiered structure might look like this: $199 for 2.5 mg weekly, $249 for 5 mg weekly, $299 for 7.5 mg weekly, $349 for 10 mg weekly, and $449 for 12.5 to 15 mg weekly

Int J Obes 38(5):689697 Aroda VR et al (2023) Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes

Mechanisms for establishment of the placental glucocorticoid barrier, a guard for life